Compare NVEC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVEC | TNGX |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.9M | 1.4B |
| IPO Year | 1996 | N/A |
| Metric | NVEC | TNGX |
|---|---|---|
| Price | $70.73 | $9.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 50.0K | ★ 2.6M |
| Earning Date | 01-21-2026 | 11-04-2025 |
| Dividend Yield | ★ 5.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.85 | N/A |
| Revenue | $24,784,396.00 | ★ $66,501,000.00 |
| Revenue This Year | N/A | $53.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.72 | ★ N/A |
| Revenue Growth | N/A | ★ 53.29 |
| 52 Week Low | $51.50 | $1.03 |
| 52 Week High | $88.50 | $11.20 |
| Indicator | NVEC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 61.79 | 52.39 |
| Support Level | $62.71 | $8.89 |
| Resistance Level | $66.26 | $10.22 |
| Average True Range (ATR) | 2.16 | 0.63 |
| MACD | 1.25 | -0.14 |
| Stochastic Oscillator | 77.96 | 20.91 |
NVE Corp develops and sells devices that use spintronics, a nanotechnology that relies on electron spin. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.